115 related articles for article (PubMed ID: 17629851)
1. Affinity and kinetics of different heparins binding to P- and L-selectin.
Simonis D; Christ K; Alban S; Bendas G
Semin Thromb Hemost; 2007 Jul; 33(5):534-9. PubMed ID: 17629851
[TBL] [Abstract][Full Text] [Related]
2. Kinetic analysis of heparin and glucan sulfates binding to P-selectin and its impact on the general understanding of selectin inhibition.
Simonis D; Fritzsche J; Alban S; Bendas G
Biochemistry; 2007 May; 46(20):6156-64. PubMed ID: 17458940
[TBL] [Abstract][Full Text] [Related]
3. Affinity and kinetics of sialyl Lewis-X and core-2 based oligosaccharides binding to L- and P-selectin.
Beauharnois ME; Lindquist KC; Marathe D; Vanderslice P; Xia J; Matta KL; Neelamegham S
Biochemistry; 2005 Jul; 44(27):9507-19. PubMed ID: 15996105
[TBL] [Abstract][Full Text] [Related]
4. Antimetastatic activities of modified heparins: selectin inhibition by heparin attenuates metastasis.
Borsig L
Semin Thromb Hemost; 2007 Jul; 33(5):540-6. PubMed ID: 17629852
[TBL] [Abstract][Full Text] [Related]
5. Heparin attenuates metastasis mainly due to inhibition of P- and L-selectin, but non-anticoagulant heparins can have additional effects.
Stevenson JL; Varki A; Borsig L
Thromb Res; 2007; 120 Suppl 2():S107-11. PubMed ID: 18023703
[TBL] [Abstract][Full Text] [Related]
6. Generic low-molecular-weight heparins: some practical considerations.
Fareed J; Leong WL; Hoppensteadt DA; Jeske WP; Walenga J; Wahi R; Bick RL
Semin Thromb Hemost; 2004 Dec; 30(6):703-13. PubMed ID: 15630677
[TBL] [Abstract][Full Text] [Related]
7. The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on bloodborne metastasis in vivo.
Ludwig RJ; Alban S; Bistrian R; Boehncke WH; Kaufmann R; Henschler R; Gille J
Thromb Haemost; 2006 Mar; 95(3):535-40. PubMed ID: 16525583
[TBL] [Abstract][Full Text] [Related]
8. Melanoma cell adhesion can be blocked by heparin in vitro: suggestion of VLA-4 as a novel target for antimetastatic approaches.
Fritzsche J; Simonis D; Bendas G
Thromb Haemost; 2008 Dec; 100(6):1166-75. PubMed ID: 19132244
[TBL] [Abstract][Full Text] [Related]
9. Distinct kinetic and mechanical properties govern selectin-leukocyte interactions.
Hanley WD; Wirtz D; Konstantopoulos K
J Cell Sci; 2004 May; 117(Pt 12):2503-11. PubMed ID: 15159451
[TBL] [Abstract][Full Text] [Related]
10. Differential metastasis inhibition by clinically relevant levels of heparins--correlation with selectin inhibition, not antithrombotic activity.
Stevenson JL; Choi SH; Varki A
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):7003-11. PubMed ID: 16203794
[TBL] [Abstract][Full Text] [Related]
11. The influence of various structural parameters of semisynthetic sulfated polysaccharides on the P-selectin inhibitory capacity.
Fritzsche J; Alban S; Ludwig RJ; Rubant S; Boehncke WH; Schumacher G; Bendas G
Biochem Pharmacol; 2006 Aug; 72(4):474-85. PubMed ID: 16780802
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of antiinflammatory and antiadhesive effects of heparins in human endotoxemia.
Derhaschnig U; Pernerstorfer T; Knechtelsdorfer M; Hollenstein U; Panzer S; Jilma B
Crit Care Med; 2003 Apr; 31(4):1108-12. PubMed ID: 12682480
[TBL] [Abstract][Full Text] [Related]
13. Antimetastatic activities of heparins and modified heparins. Experimental evidence.
Borsig L
Thromb Res; 2010 Apr; 125 Suppl 2():S66-71. PubMed ID: 20434009
[TBL] [Abstract][Full Text] [Related]
14. Selectin/glycoconjugate binding assays for the identification and optimization of selectin antagonists.
Weitz-Schmidt G; Gong KW; Wong CH
Anal Biochem; 1999 Aug; 273(1):81-8. PubMed ID: 10452802
[TBL] [Abstract][Full Text] [Related]
15. Fragment profiling of low molecular weight heparins using reversed phase ion pair liquid chromatography-electrospray mass spectrometry.
Xu X; Li D; Chi L; Du X; Bai X; Chi L
Carbohydr Res; 2015 Apr; 407():26-33. PubMed ID: 25701653
[TBL] [Abstract][Full Text] [Related]
16. Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents.
Koenig A; Norgard-Sumnicht K; Linhardt R; Varki A
J Clin Invest; 1998 Feb; 101(4):877-89. PubMed ID: 9466983
[TBL] [Abstract][Full Text] [Related]
17. Mapping of low molecular weight heparins using reversed phase ion pair liquid chromatography-mass spectrometry.
Li D; Chi L; Jin L; Xu X; Du X; Ji S; Chi L
Carbohydr Polym; 2014 Jan; 99():339-44. PubMed ID: 24274516
[TBL] [Abstract][Full Text] [Related]
18. The inhibition of the integrin VLA-4 in MV3 melanoma cell binding by non-anticoagulant heparin derivatives.
Schlesinger M; Schmitz P; Zeisig R; Naggi A; Torri G; Casu B; Bendas G
Thromb Res; 2012 May; 129(5):603-10. PubMed ID: 22099706
[TBL] [Abstract][Full Text] [Related]
19. Microvascular effects of the low molecular weight heparins in a colorectal xenograft model: an intravital microscopy study.
Debergh I; Pattyn P; Ceelen W
J Surg Res; 2015 Apr; 194(2):488-495. PubMed ID: 25466520
[TBL] [Abstract][Full Text] [Related]
20. Selectins--potential pharmacological targets?
Kneuer C; Ehrhardt C; Radomski MW; Bakowsky U
Drug Discov Today; 2006 Nov; 11(21-22):1034-40. PubMed ID: 17055414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
